Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram, Copper Gluconate, and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
NCT05210374Phase 1Recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disulfiram in sarcoma, sponsored by Case Comprehensive Cancer Center. Primary endpoints: Percent of participants experiencing grade 3+ adverse events, Recommended phase 2 dose and 3 more. Started Mar 2023; status: recruiting.
02
Drugs
disulfiram
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT05210374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210374.